SCHEMBL8570307

SCHEMBL8570307

CCOC(=O)/C=C/c1ccc(C(=O)OC(C)(C)C)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.61
CA1 P00915 1/20 0.61
CA2 P00918 1/20 0.61
CA7 P43166 1/20 0.61
CA9 Q16790 1/20 0.61
CA14 Q9ULX7 1/20 0.61
CYP3A4 P08684 2/20 0.55
TTR P02766 1/20 0.54
DPP4 P27487 1/20 0.54
ESR1 P03372 1/20 0.49
MAOB P27338 3/20 0.49
PTGS2 P35354 1/20 0.47
FDPS P14324 1/20 0.47
MAPT P10636 1/20 0.44
POLB P06746 1/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
ALOX5 P09917 1/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8570311 1.00 CA12 (0.61) CA12CA1CA2CA7CA9
SCHEMBL17002902 0.89 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL17002904 0.89 CA12 (0.54) CA12CA1CA2CA7CA9
SCHEMBL1579754 0.88 CA12 (0.69) CA12CA1CA2CA7CA9
SCHEMBL17269622 0.86 CA12 (0.71) CA12CA1CA2CA7CA9
SCHEMBL17262390 0.86 CA12 (0.71) CA12CA1CA2CA7CA9
SCHEMBL7423972 0.84 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL7423966 0.84 CA12 (0.58) CA12CA1CA2CA7CA9
SCHEMBL10581102 0.84 CA12 (0.67) CA12CA1CA2CA7CA9
SCHEMBL10581099 0.84 CA12 (0.67) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE DIC CORPORATION (JP) 2017-09-14 US disclosed
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE DIC CORPORATION (JP) 2017-09-14 US disclosed
EP-0530579-B1 Condensed pyrimidine derivatives antitumor agents EISAI CO LTD (JP) 1998-11-11 EP disclosed
US-5688800-A ANTITUMOR AGENTS EISAI CO., LTD. (JP) 1997-11-18 US disclosed
US-5554615-A ANTITUMOR EISAI CO., LTD. (JP) 1996-09-10 US disclosed
EP-0530579-A1 Condensed pyrimidine derivatives antitumor agents Eisai Co., Ltd. (JP) 1993-03-10 EP disclosed
US-4742052-A Antibacterial β-lactam compounds SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1988-05-03 US disclosed
EP-0070204-A2 Carboxylic beta-lactam compounds and the preparation thereof SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170260150-A1 POLYMERIZABLE COMPOUND, COMPOSITION, POLYMER, OPTICALLY ANISOTROPIC BODY, LIQUID CRYSTAL DISPLAY ELEMENT, AND ORGANIC EL DEVICE RPL19, RPL24, RPL29 CA12 1946/4885CA1 1476/4885CA2 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.